FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Mulls Harmonized Device Review System: Shuren

[ Price : $8.95]

CDRH director Jeffrey Shuren says FDA and other international regulatory agencies are considering how to develop a harmonized prem...

CDRH Approves Bayer Essure Study Plan

[ Price : $8.95]

CDRH approves an updated postmarket study plan submitted by Bayer to assess safety and efficacy issues involving its controversial...

Celator Investigational Drug Misbranded: OPDP

[ Price : $8.95]

CDERs Office of Prescription Drug Promotion cautions Celator that a convention panel misbrands its investigation cancer drug CPX-3...

Sage Given Breakthrough Status for Postpartum Depression Drug

[ Price : $8.95]

FDA grants Sage Therapeutics a breakthrough therapy designation for SAGE-547 for treating postpartum depression.

Quality, Data Issues in Pan Drugs Inspection

[ Price : $8.95]

FDA warns Indias Pan Drugs about CGMP and data integrity violations in its manufacturing of finished pharmaceuticals.

BD Submits PMA for Onclarity HPV Assay

[ Price : $8.95]

BD submits a PMA application to FDA for its Onclarity HPV (human papilloma virus test.

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Central Admixture Pharmacy Services, Healing Noni Co., Healing-Scents, Jack P. H...

FDA Orphan Status for Catalyst Firdapse in New Indication

[ Price : $8.95]

FDA grants Catalyst Pharmaceuticals an orphan drug designation for Firdapse (amifampridine phosphate) for treating myasthenia grav...

Hill Letter Questions Mylan EpiPen Medicaid Rebate Classification

[ Price : $8.95]

U.S. lawmakers question Mylans classification and rebate obligations under the Medicaid Drug Rebate Program for its controversial ...

CDRH Allows Marketing of Clot Removal Device

[ Price : $8.95]

CDRH allows under its de novo review the marketing of Concentric Medicals two Trevo clot retrieval devices as an initial therapy f...